Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, BTXA treatment was reported to effectively increase hair density and improve follicle health in androgenetic alopecia patients by enhancing scalp blood flow and reducing inflammation, without significant adverse effects.

This study tested the acute toxicity of Ficus platyphylla methanol leaf extract in Wistar rats and found no mortality or significant liver enzyme changes at doses up to 5000 mg/kg, suggesting a high margin of acute safety and supporting its traditional use under short-term exposure.

This study found that the methanol leaf extract of Ficus platyphylla demonstrated a high margin of acute safety in Wistar rats, showing minimal risk under short-term exposure with no mortality at doses up to 5000 mg/kg and no significant changes in liver enzyme activities.

This registered trial will investigate whether preoperative botulinum toxin can improve hair transplantation outcomes by enhancing blood flow and reducing ischemia in the scalp.

This article outlines a randomized trial to evaluate whether preoperative botulinum toxin administration can improve hair transplantation outcomes by reducing ischemia-induced graft failure.

In this review, researchers examined nine studies on botulinum toxin type A's effects on biomarkers in chronic head and neck conditions, finding significant, though low to moderate certainty, changes in markers like CGRP and serotonin associated with inflammation and mood disorders.

This study outlines a randomized trial investigating the effects of botulinum toxin administered before hair transplantation to potentially improve outcomes by enhancing blood flow and reducing graft failure due to ischemia in androgenetic alopecia patients.

This study outlines a randomized trial to assess if administering botulinum toxin before hair transplantation can improve outcomes by enhancing blood flow and reducing ischemia-induced graft failure in patients with androgenetic alopecia.

This study explores the hypothesis that preoperative administration of botulinum toxin could enhance hair transplantation outcomes by improving scalp microenvironment and reducing ischemia-induced graft failure, using a randomized split-scalp controlled trial design.

In this study, researchers found that type A botulinum toxin injections can reduce hypertrophic scars effectively, though more high-quality studies are needed to confirm the precision and stability of these therapeutic effects.

This review reports that while botulinum toxin shows potential mechanisms for treating androgenetic alopecia, recent high-quality trials found no significant hair density improvement compared to placebo, indicating it can't yet replace traditional treatments.

This study suggests an association between glyoxylic acid-containing hair-straightening treatments and acute kidney injury in young women, with urine calcium oxalate crystals observed in some cases, indicating potential nephrotoxicity. Early treatment with thiamine and pyridoxine may mitigate the severity of kidney damage.

Topical minoxidil is dangerous for cats and dogs.

This study found that a single session of botulinum toxin, whether administered subcutaneously or combined intramuscularly and subcutaneously, did not significantly improve hair density or hair quality in men with androgenetic alopecia after six months.

This paper highlights the emerging trend of treating androgenic alopecia with botulinum toxin, despite insufficient scientific evidence supporting its effectiveness.

This study found that both intralesional minoxidil 8% and botulinum toxin type A were equally effective in treating female pattern hair loss, with no significant difference in results between the two treatments.

The study did not find evidence to support using botulinum toxin as a treatment for androgenetic alopecia.

This review discusses the various therapeutic uses of Botulinum Toxin Type A and reports high levels of patient satisfaction with minimal adverse effects across several conditions, emphasizing its potential therapeutic importance.

The study found that botulinum toxin-A significantly increased the diameter of the supratrochlear artery in a small patient group, suggesting potential vasodilatory benefits for treating ischemic conditions.

This case report describes a 34-year-old Asian female who experienced prolonged localized facial blanching following botulinum toxin type A injection, marking the first such documented case in this population.

This meta-analysis and systematic review found that botulinum toxin injections significantly increased hair count in patients with androgenetic alopecia compared to controls, indicating promising efficacy and good safety.

This study evaluated the potential toxicity of oral dihydroartemisinin in SD rats, finding that female rats experienced greater toxic effects than males, particularly at higher doses, but these effects were reversible after a 4-week recovery period.

In this randomized, controlled, clinical trial, the researchers found that injectable botulinum toxin did not promote hair growth in men with androgenetic alopecia over 12 or 24 weeks, showing no benefit in improving hair density compared to placebo.

In this case report, the authors observed that onabotulinum toxin A therapy, extended to areas around traumatic excoriations and alopecia, resulted in notable healing and hair regrowth in a patient with trigeminal trophic syndrome and trichotillomania.

This study proposes that intranasal exposure to PTx and autoantigen in an animal model can trigger autoimmune disease, supporting the idea that subclinical nasal colonization by BP may cause alopecia areata.

This study found that both intradermal botulinum toxin A and intradermal minoxidil were equally effective for treating androgenetic alopecia, showing improvement in hair count with advantages like minimal invasiveness and absence of major side effects; minoxidil was also noted to be more cost-effective.

Botulinum toxin is not effective for treating male hair loss.

Botulinum toxin is not effective or cost-efficient for treating male pattern baldness.

This study found that in male patients with androgenetic alopecia, combining botulinum toxin type A with 5% Minoxidil significantly improved hair growth, patient satisfaction, and quality of life over six months, compared to using Minoxidil alone, without causing adverse effects.